GLP-1 medications have become a major topic in weight management, diabetes care, and obesity medicine. Medications such as Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, and newer oral options are commonly discussed by patients, clinicians, insurers, and public health experts.
This guide explains what GLP-1 medications are, how they may support weight management, what clinical studies have shown, what side effects are commonly reported, and what questions to discuss with a licensed healthcare professional.
This article is for general educational purposes only. It is not medical advice, diagnosis, treatment guidance, or a recommendation for any specific medication.
In This Article
- What Is GLP-1?
- How GLP-1 Medications May Support Weight Loss
- What Clinical Studies Show About Weight Loss Results
- What Some People May Notice Early in Treatment
- GLP-1 Medication Comparison
- Side Effects and Safety Considerations
- Who May Qualify for GLP-1 Weight Management Treatment
- Cost, Insurance, and Compounded GLP-1s
- Lifestyle Support During GLP-1 Treatment
- Frequently Asked Questions
- Sources
1. What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It is a hormone naturally released in the gut after eating.
GLP-1 plays a role in appetite, digestion, and blood sugar regulation. It can help signal fullness, support insulin release when blood sugar rises, and slow how quickly food leaves the stomach.
GLP-1 receptor agonist medications are designed to act on similar pathways. Some are approved for type 2 diabetes, some are approved for chronic weight management, and some have more than one approved use depending on the brand and formulation.
GLP-1 medications are prescription drugs and should only be used under the supervision of a licensed healthcare professional.
2. How GLP-1 Medications May Support Weight Loss
GLP-1-based medications may support weight loss through several biological pathways.
They May Reduce Appetite
Many people taking GLP-1 medications report feeling less hungry or feeling full sooner. This does not happen the same way for everyone, and appetite changes can vary by medication, dose, tolerance, and individual health factors.
They May Slow Stomach Emptying
GLP-1 medications can slow gastric emptying, which may help some people feel full for longer after eating. This same effect can also contribute to gastrointestinal side effects, such as nausea, reflux, constipation, or abdominal discomfort.
They May Affect Food-Related Reward Signals
GLP-1 receptors are found in areas involved in appetite and reward. Researchers continue to study how these medications influence cravings, eating behavior, and the experience some people describe as “food noise.”
They May Improve Blood Sugar Regulation
Some GLP-1 medications are used in type 2 diabetes because they help the body manage blood sugar. People with diabetes or insulin-related conditions should be monitored by a healthcare professional while using these medications.
Important Note
GLP-1 medications are not a substitute for medical care, nutrition support, physical activity, or long-term weight management planning. Their potential benefits and risks should be reviewed with a qualified clinician.
3. What Clinical Studies Show About Weight Loss Results
Clinical trials have shown that some GLP-1 and related medications can lead to clinically meaningful weight loss in adults with obesity or overweight with weight-related health conditions.
The FDA approved Zepbound, which contains tirzepatide, for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition, in addition to reduced-calorie eating and increased physical activity. In one FDA-reviewed trial of adults without diabetes, participants receiving the highest approved Zepbound dose lost an average of 18% of body weight after 72 weeks, compared with placebo.
A head-to-head clinical trial comparing tirzepatide and semaglutide found greater average weight reduction with tirzepatide than semaglutide over 72 weeks. The SURMOUNT-5 trial reported a 20.2% average weight reduction with tirzepatide compared with 13.7% with semaglutide in adults with obesity but without diabetes.
These results are trial averages. They should not be interpreted as guaranteed individual results.
Results Can Vary Widely
Factors that may influence results include:
Starting weight
Medical history
Medication selected
Tolerance and side effects
Consistency with prescribed treatment
Nutrition quality
Physical activity
Sleep
Other medications
Insurance access
Continuity of care
Some people lose more weight than the average reported in trials. Others lose less or stop treatment because of side effects, cost, access issues, or personal preference.
4. What Some People May Notice Early in Treatment
Early experiences with GLP-1 medications vary. Some people notice appetite changes within the first few weeks, while others notice more gradual changes. Some people experience side effects before they notice weight changes.
Possible early experiences may include:
Reduced appetite
Feeling full sooner
Nausea
Constipation or diarrhea
Heartburn or reflux
Changes in food preferences
Slower eating
Smaller portion sizes
Not everyone experiences these effects. A healthcare professional can help evaluate whether symptoms are expected, manageable, or a reason to adjust or stop treatment.
Avoid making changes to a prescription medication without speaking with the prescribing clinician.
5. GLP-1 Medication Comparison
Medication selection should be individualized. A clinician may consider medical history, contraindications, insurance coverage, medication availability, tolerance, other prescriptions, and patient preference.
Ozempic
Active ingredient: Semaglutide
Common FDA-approved use: Type 2 diabetes
Weight management status: Ozempic is not the dedicated obesity brand, though weight change is commonly discussed in relation to semaglutide.
Form: Injectable
Wegovy
Active ingredient: Semaglutide
Common FDA-approved use: Chronic weight management in qualifying patients
Additional FDA-approved indication: Wegovy is also approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
Form: Injectable
Zepbound
Active ingredient: Tirzepatide
Common FDA-approved use: Chronic weight management in qualifying adults with obesity or overweight with at least one weight-related condition
Form: Injectable
FDA notes that Zepbound is used in addition to reduced-calorie eating and increased physical activity.
Mounjaro
Active ingredient: Tirzepatide
Common FDA-approved use: Type 2 diabetes
Weight management status: Mounjaro is not the dedicated obesity brand, though weight change is commonly discussed in relation to tirzepatide.
Form: Injectable
Foundayo
Active ingredient: Orforglipron
Common FDA-approved use: Chronic weight management in qualifying adults with obesity or overweight with at least one weight-related comorbid condition
Form: Oral tablet
The FDA approved Foundayo in 2026 for use with reduced-calorie eating and increased physical activity to reduce excess body weight and maintain weight reduction long term in qualifying adults.
Saxenda
Active ingredient: Liraglutide
Common FDA-approved use: Chronic weight management in qualifying adults and certain pediatric patients
Form: Injectable
6. Side Effects and Safety Considerations
GLP-1 and related medications can cause side effects. The most commonly reported side effects are gastrointestinal.
Commonly Reported Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort or pain
Heartburn or reflux
Fatigue
Burping
Injection-site reactions for injectable products
Changes in appetite
Hair loss in some patients
The FDA lists nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, injection-site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease among possible side effects for Zepbound.
Less Common but More Serious Safety Concerns
Some GLP-1 and related medications carry warnings or precautions for:
Pancreatitis
Gallbladder problems
Severe gastrointestinal symptoms
Kidney injury related to dehydration from severe vomiting or diarrhea
Low blood sugar when used with certain diabetes medications
Allergic reactions
Diabetic retinopathy concerns in some patients with diabetes
Potential thyroid C-cell tumor risk warnings
Wegovy’s FDA safety information includes a boxed warning related to thyroid C-cell tumors and states it should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
People taking GLP-1 medications should report concerning or persistent symptoms to their healthcare professional. This article does not provide instructions for managing medication side effects.
7. Who May Qualify for GLP-1 Weight Management Treatment
FDA-approved chronic weight management medications are generally intended for adults who meet specific clinical criteria.
For Zepbound, FDA approval applies to adults with obesity, defined as a body mass index of 30 or higher, or adults with overweight, defined as a body mass index of 27 or higher, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
A healthcare professional may also review:
Medical history
Current medications
Pregnancy status or pregnancy plans
History of pancreatitis or gallbladder disease
History of thyroid cancer or MEN 2
Diabetes status
Kidney function
Digestive conditions
Mental health history
Previous weight management attempts
Insurance requirements
BMI alone does not determine whether a medication is appropriate. The decision should be based on a full clinical evaluation.
8. Cost, Insurance, and Compounded GLP-1s
GLP-1 medications can be expensive without insurance. Out-of-pocket cost may depend on:
Medication selected
Insurance plan
Diagnosis and prior authorization requirements
Manufacturer savings programs
Pharmacy availability
Dose and formulation
Whether the medication is FDA-approved or compounded
Insurance coverage can vary significantly. Some plans cover GLP-1 medications for type 2 diabetes but not for weight management. Others may cover obesity treatment when specific clinical criteria are met.
Compounded GLP-1s Require Caution
Compounded drugs are not the same as FDA-approved medications.
Patients considering compounded products should discuss risks, legality, sourcing, and quality concerns with a licensed healthcare professional and pharmacist.
9. Lifestyle Support During GLP-1 Treatment
GLP-1 medications are usually discussed as part of a broader care plan. Lifestyle support can matter for nutrition, muscle preservation, metabolic health, and long-term maintenance.
Support areas may include:
Balanced nutrition
Adequate protein intake based on individual needs
Strength or resistance-based activity when appropriate
Regular movement
Sleep support
Hydration
Monitoring for side effects
Behavioral support
Follow-up with a healthcare professional
Support from a registered dietitian when available
Because appetite may decrease, some people may unintentionally eat too little or miss important nutrients. A clinician or registered dietitian can help personalize nutrition goals.
Stopping medication may be associated with weight regain for some patients. The SURMOUNT-4 randomized clinical trial found that withdrawing tirzepatide led to substantial regain of lost weight, while continued treatment helped maintain or improve weight reduction.
Any decision to continue, pause, switch, or stop a prescription medication should be made with the prescribing healthcare professional.
10. Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Ozempic and Wegovy both contain semaglutide, but they are approved for different primary uses. Ozempic is commonly used for type 2 diabetes, while Wegovy is the semaglutide brand approved for chronic weight management in qualifying patients.
A healthcare professional can explain which, if either, is appropriate based on diagnosis, goals, and medical history.
Do you have to stay on GLP-1 medication forever?
Not necessarily. However, obesity is often a chronic condition, and research suggests that some people regain weight after stopping GLP-1 or related medications. Long-term planning should be individualized and discussed with a healthcare professional.
Can someone take GLP-1 medication without diabetes?
Some GLP-1 or related medications are approved for chronic weight management in adults who meet clinical criteria, even if they do not have diabetes. Eligibility depends on the specific medication, BMI, weight-related conditions, safety factors, and clinician evaluation.
Is there an oral GLP-1 option for weight management?
Yes. The FDA approved Foundayo, which contains orforglipron, as an oral GLP-1 receptor agonist in tablet form for qualifying adults with obesity or overweight with at least one weight-related comorbid condition.
How quickly do GLP-1 medications work?
Some people notice appetite changes early, while others notice gradual changes over time. Weight loss varies widely and should not be expected on a fixed timeline. A healthcare professional can help set realistic expectations.
What foods should be avoided while taking GLP-1 medications?
This article does not provide medication-specific diet instructions. Some people report that rich, greasy, or large meals worsen digestive side effects, but individual tolerance varies. A healthcare professional or registered dietitian can provide personalized guidance.
Are GLP-1 medications safe?
GLP-1 medications have been studied in clinical trials and approved for specific uses, but they are not risk-free. They may cause side effects and may not be appropriate for people with certain medical histories. Safety should be reviewed with a licensed healthcare professional.
Are compounded GLP-1 medications FDA-approved?
No. Compounded medications are not FDA-approved in the same way as branded prescription drugs. Patients should discuss compounded products with a licensed healthcare professional and pharmacist before considering them.
The Bottom Line
GLP-1 and related medications have become important options in obesity medicine and diabetes care. Clinical studies show that some of these medications can support meaningful weight loss for qualifying adults, but results vary and are not guaranteed.
These medications also come with side effects, safety warnings, cost concerns, and access limitations. They are prescription treatments and should only be considered through a licensed healthcare professional.
For anyone considering GLP-1 treatment, the safest next step is a medical evaluation that reviews health history, medication options, risks, benefits, cost, and long-term support.
Medical Disclaimer
This article is for informational and educational purposes only. It does not provide medical advice, diagnosis, treatment instructions, dosage guidance, or medication recommendations. GLP-1 and related medications are prescription drugs that require evaluation and monitoring by a licensed healthcare professional. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Individual results vary.
Sources
U.S. Food and Drug Administration: Zepbound approval for chronic weight management.
U.S. Food and Drug Administration: Wegovy cardiovascular risk reduction indication and safety information.
U.S. Food and Drug Administration: Foundayo approval information.
PubMed: Tirzepatide compared with semaglutide for obesity treatment, SURMOUNT-5.
New England Journal of Medicine: SURMOUNT-5 trial results.
